nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ALB—hematologic cancer	0.0797	0.512	CbGaD
Fluoxetine—ABCB1—hematologic cancer	0.0761	0.488	CbGaD
Fluoxetine—ORM1—Imatinib—hematologic cancer	0.0211	0.0401	CbGbCtD
Fluoxetine—CYP1A2—Anagrelide—hematologic cancer	0.0171	0.0324	CbGbCtD
Fluoxetine—CYP2B6—Thiotepa—hematologic cancer	0.0167	0.0317	CbGbCtD
Fluoxetine—CYP2C9—Bexarotene—hematologic cancer	0.0107	0.0202	CbGbCtD
Fluoxetine—ABCB1—Lenalidomide—hematologic cancer	0.0104	0.0196	CbGbCtD
Fluoxetine—CYP2B6—Ifosfamide—hematologic cancer	0.00949	0.018	CbGbCtD
Fluoxetine—CYP3A5—Daunorubicin—hematologic cancer	0.00932	0.0177	CbGbCtD
Fluoxetine—CYP2D6—Lomustine—hematologic cancer	0.00907	0.0172	CbGbCtD
Fluoxetine—CYP1A2—Carmustine—hematologic cancer	0.00897	0.017	CbGbCtD
Fluoxetine—ALB—Imatinib—hematologic cancer	0.00889	0.0169	CbGbCtD
Fluoxetine—CYP2C9—Idarubicin—hematologic cancer	0.00884	0.0168	CbGbCtD
Fluoxetine—CYP3A5—Thalidomide—hematologic cancer	0.00849	0.0161	CbGbCtD
Fluoxetine—CYP2B6—Nilotinib—hematologic cancer	0.00824	0.0156	CbGbCtD
Fluoxetine—CYP3A5—Teniposide—hematologic cancer	0.0081	0.0154	CbGbCtD
Fluoxetine—CYP2D6—Idarubicin—hematologic cancer	0.00808	0.0153	CbGbCtD
Fluoxetine—CYP2C19—Bortezomib—hematologic cancer	0.00786	0.0149	CbGbCtD
Fluoxetine—CYP1A2—Methoxsalen—hematologic cancer	0.00763	0.0145	CbGbCtD
Fluoxetine—CYP3A5—Ifosfamide—hematologic cancer	0.00748	0.0142	CbGbCtD
Fluoxetine—CYP1A2—Bortezomib—hematologic cancer	0.00725	0.0138	CbGbCtD
Fluoxetine—CYP3A5—Imatinib—hematologic cancer	0.00714	0.0136	CbGbCtD
Fluoxetine—CYP1A2—Daunorubicin—hematologic cancer	0.00694	0.0132	CbGbCtD
Fluoxetine—CYP2D6—Hydroxyurea—hematologic cancer	0.00687	0.013	CbGbCtD
Fluoxetine—CYP2C19—Thalidomide—hematologic cancer	0.00685	0.013	CbGbCtD
Fluoxetine—CYP1A2—Alitretinoin—hematologic cancer	0.0068	0.0129	CbGbCtD
Fluoxetine—CYP2C9—Bortezomib—hematologic cancer	0.00654	0.0124	CbGbCtD
Fluoxetine—CYP2C19—Teniposide—hematologic cancer	0.00653	0.0124	CbGbCtD
Fluoxetine—CYP1A2—Thalidomide—hematologic cancer	0.00632	0.012	CbGbCtD
Fluoxetine—CYP3A4—Bexarotene—hematologic cancer	0.0062	0.0118	CbGbCtD
Fluoxetine—ABCB1—Daunorubicin—hematologic cancer	0.00607	0.0115	CbGbCtD
Fluoxetine—CYP2C19—Ifosfamide—hematologic cancer	0.00603	0.0114	CbGbCtD
Fluoxetine—CYP2D6—Bortezomib—hematologic cancer	0.00598	0.0113	CbGbCtD
Fluoxetine—ABCB1—Alitretinoin—hematologic cancer	0.00594	0.0113	CbGbCtD
Fluoxetine—ALB—Prednisone—hematologic cancer	0.00585	0.0111	CbGbCtD
Fluoxetine—CYP3A4—Lomustine—hematologic cancer	0.00577	0.0109	CbGbCtD
Fluoxetine—CYP3A4—Busulfan—hematologic cancer	0.00577	0.0109	CbGbCtD
Fluoxetine—CYP2C19—Imatinib—hematologic cancer	0.00576	0.0109	CbGbCtD
Fluoxetine—CYP3A5—Dasatinib—hematologic cancer	0.00574	0.0109	CbGbCtD
Fluoxetine—CYP2C9—Thalidomide—hematologic cancer	0.00569	0.0108	CbGbCtD
Fluoxetine—CYP2B6—Irinotecan—hematologic cancer	0.00566	0.0107	CbGbCtD
Fluoxetine—ALB—Irinotecan—hematologic cancer	0.00555	0.0105	CbGbCtD
Fluoxetine—CYP1A2—Dacarbazine—hematologic cancer	0.00543	0.0103	CbGbCtD
Fluoxetine—CYP2C9—Teniposide—hematologic cancer	0.00543	0.0103	CbGbCtD
Fluoxetine—CYP1A2—Imatinib—hematologic cancer	0.00532	0.0101	CbGbCtD
Fluoxetine—CYP3A4—Thiotepa—hematologic cancer	0.00514	0.00975	CbGbCtD
Fluoxetine—CYP2C9—Ifosfamide—hematologic cancer	0.00501	0.00951	CbGbCtD
Fluoxetine—CYP2C9—Imatinib—hematologic cancer	0.00479	0.00909	CbGbCtD
Fluoxetine—ABCB1—Imatinib—hematologic cancer	0.00465	0.00882	CbGbCtD
Fluoxetine—CYP2B6—Cisplatin—hematologic cancer	0.00462	0.00876	CbGbCtD
Fluoxetine—CYP3A5—Irinotecan—hematologic cancer	0.00446	0.00846	CbGbCtD
Fluoxetine—CYP2D6—Imatinib—hematologic cancer	0.00438	0.00831	CbGbCtD
Fluoxetine—CYP2C9—Nilotinib—hematologic cancer	0.00435	0.00826	CbGbCtD
Fluoxetine—CYP1A2—Dasatinib—hematologic cancer	0.00427	0.0081	CbGbCtD
Fluoxetine—ABCB1—Nilotinib—hematologic cancer	0.00422	0.00802	CbGbCtD
Fluoxetine—ABCB1—Vinorelbine—hematologic cancer	0.00419	0.00795	CbGbCtD
Fluoxetine—CYP3A4—Methoxsalen—hematologic cancer	0.004	0.00758	CbGbCtD
Fluoxetine—CYP2D6—Nilotinib—hematologic cancer	0.00398	0.00755	CbGbCtD
Fluoxetine—CYP2D6—Vinorelbine—hematologic cancer	0.00395	0.00749	CbGbCtD
Fluoxetine—CYP3A5—Vincristine—hematologic cancer	0.0039	0.0074	CbGbCtD
Fluoxetine—CYP3A4—Bortezomib—hematologic cancer	0.0038	0.00721	CbGbCtD
Fluoxetine—CYP2C19—Prednisone—hematologic cancer	0.0038	0.0072	CbGbCtD
Fluoxetine—ABCB1—Dasatinib—hematologic cancer	0.00373	0.00708	CbGbCtD
Fluoxetine—CYP2B6—Dexamethasone—hematologic cancer	0.00373	0.00708	CbGbCtD
Fluoxetine—ABCB1—Mitoxantrone—hematologic cancer	0.00369	0.007	CbGbCtD
Fluoxetine—CYP3A4—Daunorubicin—hematologic cancer	0.00364	0.0069	CbGbCtD
Fluoxetine—CYP3A5—Etoposide—hematologic cancer	0.00357	0.00678	CbGbCtD
Fluoxetine—ABCB1—Betamethasone—hematologic cancer	0.00329	0.00624	CbGbCtD
Fluoxetine—ABCB1—Gemcitabine—hematologic cancer	0.00326	0.00618	CbGbCtD
Fluoxetine—ABCB1—Prednisolone—hematologic cancer	0.00324	0.00615	CbGbCtD
Fluoxetine—CYP3A4—Cytarabine—hematologic cancer	0.00321	0.00609	CbGbCtD
Fluoxetine—CYP3A4—Teniposide—hematologic cancer	0.00316	0.00599	CbGbCtD
Fluoxetine—CYP2B6—Doxorubicin—hematologic cancer	0.00309	0.00587	CbGbCtD
Fluoxetine—ABCB1—Prednisone—hematologic cancer	0.00306	0.00581	CbGbCtD
Fluoxetine—CYP3A5—Dexamethasone—hematologic cancer	0.00294	0.00557	CbGbCtD
Fluoxetine—ALB—Methotrexate—hematologic cancer	0.00294	0.00557	CbGbCtD
Fluoxetine—CYP3A4—Ifosfamide—hematologic cancer	0.00292	0.00553	CbGbCtD
Fluoxetine—ABCB1—Irinotecan—hematologic cancer	0.0029	0.00551	CbGbCtD
Fluoxetine—CYP3A4—Imatinib—hematologic cancer	0.00278	0.00528	CbGbCtD
Fluoxetine—CYP1A2—Etoposide—hematologic cancer	0.00266	0.00505	CbGbCtD
Fluoxetine—CYP3A4—Ruxolitinib—hematologic cancer	0.00262	0.00498	CbGbCtD
Fluoxetine—ABCB1—Vinblastine—hematologic cancer	0.00258	0.0049	CbGbCtD
Fluoxetine—ABCB1—Vincristine—hematologic cancer	0.00254	0.00482	CbGbCtD
Fluoxetine—CYP3A4—Nilotinib—hematologic cancer	0.00253	0.0048	CbGbCtD
Fluoxetine—CYP3A4—Vinorelbine—hematologic cancer	0.00251	0.00476	CbGbCtD
Fluoxetine—CYP2C9—Cisplatin—hematologic cancer	0.00244	0.00463	CbGbCtD
Fluoxetine—CYP2D6—Vinblastine—hematologic cancer	0.00243	0.00462	CbGbCtD
Fluoxetine—CYP2C19—Dexamethasone—hematologic cancer	0.00237	0.0045	CbGbCtD
Fluoxetine—ABCB1—Cisplatin—hematologic cancer	0.00237	0.00449	CbGbCtD
Fluoxetine—ABCB1—Etoposide—hematologic cancer	0.00233	0.00441	CbGbCtD
Fluoxetine—CYP3A4—Triamcinolone—hematologic cancer	0.0023	0.00436	CbGbCtD
Fluoxetine—CYP3A4—Dasatinib—hematologic cancer	0.00224	0.00424	CbGbCtD
Fluoxetine—CYP3A4—Mitoxantrone—hematologic cancer	0.00221	0.00419	CbGbCtD
Fluoxetine—CYP2C9—Dexamethasone—hematologic cancer	0.00197	0.00374	CbGbCtD
Fluoxetine—CYP3A4—Betamethasone—hematologic cancer	0.00197	0.00374	CbGbCtD
Fluoxetine—CYP3A4—Prednisolone—hematologic cancer	0.00194	0.00369	CbGbCtD
Fluoxetine—ABCB1—Dexamethasone—hematologic cancer	0.00191	0.00363	CbGbCtD
Fluoxetine—CYP3A4—Prednisone—hematologic cancer	0.00183	0.00348	CbGbCtD
Fluoxetine—CYP2D6—Dexamethasone—hematologic cancer	0.0018	0.00342	CbGbCtD
Fluoxetine—CYP3A4—Irinotecan—hematologic cancer	0.00174	0.0033	CbGbCtD
Fluoxetine—ABCB1—Doxorubicin—hematologic cancer	0.00159	0.00301	CbGbCtD
Fluoxetine—CYP3A4—Vinblastine—hematologic cancer	0.00155	0.00293	CbGbCtD
Fluoxetine—ABCB1—Methotrexate—hematologic cancer	0.00154	0.00292	CbGbCtD
Fluoxetine—CYP3A4—Vincristine—hematologic cancer	0.00152	0.00289	CbGbCtD
Fluoxetine—CYP2D6—Doxorubicin—hematologic cancer	0.00149	0.00284	CbGbCtD
Fluoxetine—CYP3A4—Etoposide—hematologic cancer	0.00139	0.00264	CbGbCtD
Fluoxetine—CYP3A4—Dexamethasone—hematologic cancer	0.00115	0.00217	CbGbCtD
Fluoxetine—CYP3A4—Doxorubicin—hematologic cancer	0.00095	0.0018	CbGbCtD
Fluoxetine—ORM1—hematopoietic system—hematologic cancer	0.000864	0.047	CbGeAlD
Fluoxetine—SLC6A4—hematopoietic system—hematologic cancer	0.000736	0.04	CbGeAlD
Fluoxetine—CYP2C19—hematopoietic system—hematologic cancer	0.00061	0.0332	CbGeAlD
Fluoxetine—ORM1—blood—hematologic cancer	0.000572	0.0311	CbGeAlD
Fluoxetine—ORM1—bone marrow—hematologic cancer	0.000554	0.0301	CbGeAlD
Fluoxetine—ORM1—lung—hematologic cancer	0.000502	0.0273	CbGeAlD
Fluoxetine—CYP1A2—hematopoietic system—hematologic cancer	0.000498	0.0271	CbGeAlD
Fluoxetine—SLC6A2—gonad—hematologic cancer	0.000493	0.0268	CbGeAlD
Fluoxetine—SLC6A4—blood—hematologic cancer	0.000488	0.0265	CbGeAlD
Fluoxetine—SIGMAR1—blood—hematologic cancer	0.000484	0.0264	CbGeAlD
Fluoxetine—CYP3A5—hematopoietic system—hematologic cancer	0.00048	0.0261	CbGeAlD
Fluoxetine—CYP2B6—hematopoietic system—hematologic cancer	0.000477	0.026	CbGeAlD
Fluoxetine—CYP2C9—hematopoietic system—hematologic cancer	0.000473	0.0257	CbGeAlD
Fluoxetine—SIGMAR1—bone marrow—hematologic cancer	0.000469	0.0255	CbGeAlD
Fluoxetine—SLC6A4—lung—hematologic cancer	0.000427	0.0233	CbGeAlD
Fluoxetine—SIGMAR1—lung—hematologic cancer	0.000424	0.0231	CbGeAlD
Fluoxetine—ALB—testis—hematologic cancer	0.000415	0.0226	CbGeAlD
Fluoxetine—CYP2C19—blood—hematologic cancer	0.000404	0.022	CbGeAlD
Fluoxetine—SIGMAR1—testis—hematologic cancer	0.000401	0.0218	CbGeAlD
Fluoxetine—HTR2A—hematopoietic system—hematologic cancer	0.000389	0.0212	CbGeAlD
Fluoxetine—SLC6A2—lung—hematologic cancer	0.000376	0.0205	CbGeAlD
Fluoxetine—CYP2B6—gonad—hematologic cancer	0.000363	0.0198	CbGeAlD
Fluoxetine—CYP3A4—hematopoietic system—hematologic cancer	0.00036	0.0196	CbGeAlD
Fluoxetine—SLC6A2—testis—hematologic cancer	0.000355	0.0193	CbGeAlD
Fluoxetine—CYP2D6—hematopoietic system—hematologic cancer	0.000355	0.0193	CbGeAlD
Fluoxetine—ORM1—lymph node—hematologic cancer	0.000343	0.0187	CbGeAlD
Fluoxetine—CYP1A2—blood—hematologic cancer	0.00033	0.018	CbGeAlD
Fluoxetine—CYP3A5—blood—hematologic cancer	0.000318	0.0173	CbGeAlD
Fluoxetine—CYP2B6—blood—hematologic cancer	0.000316	0.0172	CbGeAlD
Fluoxetine—CYP2C9—blood—hematologic cancer	0.000313	0.017	CbGeAlD
Fluoxetine—ALB—lymph node—hematologic cancer	0.000301	0.0164	CbGeAlD
Fluoxetine—HTR2A—gonad—hematologic cancer	0.000296	0.0161	CbGeAlD
Fluoxetine—SIGMAR1—lymph node—hematologic cancer	0.00029	0.0158	CbGeAlD
Fluoxetine—CYP1A2—lung—hematologic cancer	0.000289	0.0157	CbGeAlD
Fluoxetine—CYP3A5—lung—hematologic cancer	0.000279	0.0152	CbGeAlD
Fluoxetine—CYP2B6—lung—hematologic cancer	0.000277	0.0151	CbGeAlD
Fluoxetine—CYP2B6—testis—hematologic cancer	0.000262	0.0142	CbGeAlD
Fluoxetine—HTR2A—blood—hematologic cancer	0.000258	0.014	CbGeAlD
Fluoxetine—SLC6A2—lymph node—hematologic cancer	0.000257	0.014	CbGeAlD
Fluoxetine—ABCB1—hematopoietic system—hematologic cancer	0.000255	0.0139	CbGeAlD
Fluoxetine—CYP3A4—blood—hematologic cancer	0.000239	0.013	CbGeAlD
Fluoxetine—CYP2D6—blood—hematologic cancer	0.000235	0.0128	CbGeAlD
Fluoxetine—HTR2A—lung—hematologic cancer	0.000226	0.0123	CbGeAlD
Fluoxetine—HTR2A—testis—hematologic cancer	0.000213	0.0116	CbGeAlD
Fluoxetine—CYP2D6—testis—hematologic cancer	0.000194	0.0106	CbGeAlD
Fluoxetine—ABCB1—gonad—hematologic cancer	0.000194	0.0106	CbGeAlD
Fluoxetine—ABCB1—blood—hematologic cancer	0.000169	0.0092	CbGeAlD
Fluoxetine—ABCB1—bone marrow—hematologic cancer	0.000164	0.0089	CbGeAlD
Fluoxetine—ABCB1—lung—hematologic cancer	0.000148	0.00807	CbGeAlD
Fluoxetine—ABCB1—testis—hematologic cancer	0.00014	0.00761	CbGeAlD
Fluoxetine—ABCB1—lymph node—hematologic cancer	0.000101	0.00552	CbGeAlD
Fluoxetine—Erythema multiforme—Doxorubicin—hematologic cancer	9.35e-06	3.73e-05	CcSEcCtD
Fluoxetine—Rash—Cisplatin—hematologic cancer	9.32e-06	3.72e-05	CcSEcCtD
Fluoxetine—Dermatitis—Cisplatin—hematologic cancer	9.31e-06	3.72e-05	CcSEcCtD
Fluoxetine—Malnutrition—Epirubicin—hematologic cancer	9.3e-06	3.71e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Etoposide—hematologic cancer	9.26e-06	3.7e-05	CcSEcCtD
Fluoxetine—Anorexia—Prednisone—hematologic cancer	9.25e-06	3.69e-05	CcSEcCtD
Fluoxetine—Ill-defined disorder—Methotrexate—hematologic cancer	9.22e-06	3.68e-05	CcSEcCtD
Fluoxetine—Tinnitus—Doxorubicin—hematologic cancer	9.22e-06	3.68e-05	CcSEcCtD
Fluoxetine—Anaemia—Methotrexate—hematologic cancer	9.18e-06	3.67e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Dexamethasone—hematologic cancer	9.18e-06	3.67e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Betamethasone—hematologic cancer	9.18e-06	3.67e-05	CcSEcCtD
Fluoxetine—Flatulence—Epirubicin—hematologic cancer	9.16e-06	3.66e-05	CcSEcCtD
Fluoxetine—Tension—Epirubicin—hematologic cancer	9.12e-06	3.64e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Dexamethasone—hematologic cancer	9.11e-06	3.64e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Betamethasone—hematologic cancer	9.11e-06	3.64e-05	CcSEcCtD
Fluoxetine—Dysgeusia—Epirubicin—hematologic cancer	9.11e-06	3.64e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Triamcinolone—hematologic cancer	9.05e-06	3.61e-05	CcSEcCtD
Fluoxetine—Nervousness—Epirubicin—hematologic cancer	9.03e-06	3.61e-05	CcSEcCtD
Fluoxetine—Back pain—Epirubicin—hematologic cancer	8.99e-06	3.59e-05	CcSEcCtD
Fluoxetine—Malaise—Methotrexate—hematologic cancer	8.96e-06	3.58e-05	CcSEcCtD
Fluoxetine—Dizziness—Etoposide—hematologic cancer	8.95e-06	3.58e-05	CcSEcCtD
Fluoxetine—Muscle spasms—Epirubicin—hematologic cancer	8.94e-06	3.57e-05	CcSEcCtD
Fluoxetine—Vertigo—Methotrexate—hematologic cancer	8.93e-06	3.57e-05	CcSEcCtD
Fluoxetine—Leukopenia—Methotrexate—hematologic cancer	8.89e-06	3.55e-05	CcSEcCtD
Fluoxetine—Chills—Doxorubicin—hematologic cancer	8.87e-06	3.54e-05	CcSEcCtD
Fluoxetine—Urticaria—Dexamethasone—hematologic cancer	8.85e-06	3.54e-05	CcSEcCtD
Fluoxetine—Urticaria—Betamethasone—hematologic cancer	8.85e-06	3.54e-05	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Prednisone—hematologic cancer	8.84e-06	3.53e-05	CcSEcCtD
Fluoxetine—Dizziness—Prednisolone—hematologic cancer	8.83e-06	3.53e-05	CcSEcCtD
Fluoxetine—Arrhythmia—Doxorubicin—hematologic cancer	8.83e-06	3.53e-05	CcSEcCtD
Fluoxetine—Asthenia—Triamcinolone—hematologic cancer	8.81e-06	3.52e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Dexamethasone—hematologic cancer	8.81e-06	3.52e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Dexamethasone—hematologic cancer	8.81e-06	3.52e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Betamethasone—hematologic cancer	8.81e-06	3.52e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Betamethasone—hematologic cancer	8.81e-06	3.52e-05	CcSEcCtD
Fluoxetine—Nausea—Cisplatin—hematologic cancer	8.78e-06	3.51e-05	CcSEcCtD
Fluoxetine—Insomnia—Prednisone—hematologic cancer	8.78e-06	3.51e-05	CcSEcCtD
Fluoxetine—Alopecia—Doxorubicin—hematologic cancer	8.73e-06	3.49e-05	CcSEcCtD
Fluoxetine—Paraesthesia—Prednisone—hematologic cancer	8.71e-06	3.48e-05	CcSEcCtD
Fluoxetine—Pruritus—Triamcinolone—hematologic cancer	8.69e-06	3.47e-05	CcSEcCtD
Fluoxetine—Cough—Methotrexate—hematologic cancer	8.67e-06	3.46e-05	CcSEcCtD
Fluoxetine—Mental disorder—Doxorubicin—hematologic cancer	8.66e-06	3.46e-05	CcSEcCtD
Fluoxetine—Ill-defined disorder—Epirubicin—hematologic cancer	8.63e-06	3.45e-05	CcSEcCtD
Fluoxetine—Convulsion—Methotrexate—hematologic cancer	8.61e-06	3.44e-05	CcSEcCtD
Fluoxetine—Vomiting—Etoposide—hematologic cancer	8.61e-06	3.44e-05	CcSEcCtD
Fluoxetine—Malnutrition—Doxorubicin—hematologic cancer	8.6e-06	3.44e-05	CcSEcCtD
Fluoxetine—Anaemia—Epirubicin—hematologic cancer	8.59e-06	3.43e-05	CcSEcCtD
Fluoxetine—Agitation—Epirubicin—hematologic cancer	8.55e-06	3.41e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Prednisone—hematologic cancer	8.54e-06	3.41e-05	CcSEcCtD
Fluoxetine—Rash—Etoposide—hematologic cancer	8.54e-06	3.41e-05	CcSEcCtD
Fluoxetine—Dermatitis—Etoposide—hematologic cancer	8.53e-06	3.41e-05	CcSEcCtD
Fluoxetine—Headache—Etoposide—hematologic cancer	8.48e-06	3.39e-05	CcSEcCtD
Fluoxetine—Flatulence—Doxorubicin—hematologic cancer	8.48e-06	3.39e-05	CcSEcCtD
Fluoxetine—Chest pain—Methotrexate—hematologic cancer	8.46e-06	3.38e-05	CcSEcCtD
Fluoxetine—Arthralgia—Methotrexate—hematologic cancer	8.46e-06	3.38e-05	CcSEcCtD
Fluoxetine—Myalgia—Methotrexate—hematologic cancer	8.46e-06	3.38e-05	CcSEcCtD
Fluoxetine—Tension—Doxorubicin—hematologic cancer	8.44e-06	3.37e-05	CcSEcCtD
Fluoxetine—Decreased appetite—Prednisone—hematologic cancer	8.44e-06	3.37e-05	CcSEcCtD
Fluoxetine—Dysgeusia—Doxorubicin—hematologic cancer	8.43e-06	3.36e-05	CcSEcCtD
Fluoxetine—Rash—Prednisolone—hematologic cancer	8.42e-06	3.36e-05	CcSEcCtD
Fluoxetine—Dermatitis—Prednisolone—hematologic cancer	8.41e-06	3.36e-05	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	8.4e-06	3.36e-05	CcSEcCtD
Fluoxetine—Malaise—Epirubicin—hematologic cancer	8.39e-06	3.35e-05	CcSEcCtD
Fluoxetine—Fatigue—Prednisone—hematologic cancer	8.37e-06	3.34e-05	CcSEcCtD
Fluoxetine—Headache—Prednisolone—hematologic cancer	8.37e-06	3.34e-05	CcSEcCtD
Fluoxetine—Discomfort—Methotrexate—hematologic cancer	8.36e-06	3.34e-05	CcSEcCtD
Fluoxetine—Nervousness—Doxorubicin—hematologic cancer	8.36e-06	3.34e-05	CcSEcCtD
Fluoxetine—Vertigo—Epirubicin—hematologic cancer	8.35e-06	3.34e-05	CcSEcCtD
Fluoxetine—Syncope—Epirubicin—hematologic cancer	8.34e-06	3.33e-05	CcSEcCtD
Fluoxetine—Leukopenia—Epirubicin—hematologic cancer	8.32e-06	3.32e-05	CcSEcCtD
Fluoxetine—Back pain—Doxorubicin—hematologic cancer	8.32e-06	3.32e-05	CcSEcCtD
Fluoxetine—Constipation—Prednisone—hematologic cancer	8.3e-06	3.31e-05	CcSEcCtD
Fluoxetine—Muscle spasms—Doxorubicin—hematologic cancer	8.27e-06	3.3e-05	CcSEcCtD
Fluoxetine—Palpitations—Epirubicin—hematologic cancer	8.22e-06	3.28e-05	CcSEcCtD
Fluoxetine—Confusional state—Methotrexate—hematologic cancer	8.18e-06	3.27e-05	CcSEcCtD
Fluoxetine—Loss of consciousness—Epirubicin—hematologic cancer	8.17e-06	3.26e-05	CcSEcCtD
Fluoxetine—Dizziness—Triamcinolone—hematologic cancer	8.12e-06	3.24e-05	CcSEcCtD
Fluoxetine—Cough—Epirubicin—hematologic cancer	8.11e-06	3.24e-05	CcSEcCtD
Fluoxetine—Anaphylactic shock—Methotrexate—hematologic cancer	8.11e-06	3.24e-05	CcSEcCtD
Fluoxetine—Convulsion—Epirubicin—hematologic cancer	8.06e-06	3.22e-05	CcSEcCtD
Fluoxetine—Infection—Methotrexate—hematologic cancer	8.06e-06	3.22e-05	CcSEcCtD
Fluoxetine—Nausea—Etoposide—hematologic cancer	8.04e-06	3.21e-05	CcSEcCtD
Fluoxetine—Hypertension—Epirubicin—hematologic cancer	8.03e-06	3.21e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Prednisone—hematologic cancer	8e-06	3.19e-05	CcSEcCtD
Fluoxetine—Asthenia—Betamethasone—hematologic cancer	7.99e-06	3.19e-05	CcSEcCtD
Fluoxetine—Asthenia—Dexamethasone—hematologic cancer	7.99e-06	3.19e-05	CcSEcCtD
Fluoxetine—Ill-defined disorder—Doxorubicin—hematologic cancer	7.98e-06	3.19e-05	CcSEcCtD
Fluoxetine—Anaemia—Doxorubicin—hematologic cancer	7.95e-06	3.18e-05	CcSEcCtD
Fluoxetine—Thrombocytopenia—Methotrexate—hematologic cancer	7.94e-06	3.17e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Prednisone—hematologic cancer	7.93e-06	3.17e-05	CcSEcCtD
Fluoxetine—Nausea—Prednisolone—hematologic cancer	7.93e-06	3.17e-05	CcSEcCtD
Fluoxetine—Arthralgia—Epirubicin—hematologic cancer	7.92e-06	3.16e-05	CcSEcCtD
Fluoxetine—Myalgia—Epirubicin—hematologic cancer	7.92e-06	3.16e-05	CcSEcCtD
Fluoxetine—Chest pain—Epirubicin—hematologic cancer	7.92e-06	3.16e-05	CcSEcCtD
Fluoxetine—Agitation—Doxorubicin—hematologic cancer	7.91e-06	3.16e-05	CcSEcCtD
Fluoxetine—Anxiety—Epirubicin—hematologic cancer	7.89e-06	3.15e-05	CcSEcCtD
Fluoxetine—Pruritus—Betamethasone—hematologic cancer	7.88e-06	3.15e-05	CcSEcCtD
Fluoxetine—Pruritus—Dexamethasone—hematologic cancer	7.88e-06	3.15e-05	CcSEcCtD
Fluoxetine—Skin disorder—Methotrexate—hematologic cancer	7.88e-06	3.15e-05	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	7.86e-06	3.14e-05	CcSEcCtD
Fluoxetine—Hyperhidrosis—Methotrexate—hematologic cancer	7.84e-06	3.13e-05	CcSEcCtD
Fluoxetine—Discomfort—Epirubicin—hematologic cancer	7.82e-06	3.12e-05	CcSEcCtD
Fluoxetine—Vomiting—Triamcinolone—hematologic cancer	7.81e-06	3.12e-05	CcSEcCtD
Fluoxetine—Malaise—Doxorubicin—hematologic cancer	7.76e-06	3.1e-05	CcSEcCtD
Fluoxetine—Rash—Triamcinolone—hematologic cancer	7.74e-06	3.09e-05	CcSEcCtD
Fluoxetine—Dry mouth—Epirubicin—hematologic cancer	7.74e-06	3.09e-05	CcSEcCtD
Fluoxetine—Dermatitis—Triamcinolone—hematologic cancer	7.74e-06	3.09e-05	CcSEcCtD
Fluoxetine—Vertigo—Doxorubicin—hematologic cancer	7.73e-06	3.09e-05	CcSEcCtD
Fluoxetine—Anorexia—Methotrexate—hematologic cancer	7.73e-06	3.09e-05	CcSEcCtD
Fluoxetine—Syncope—Doxorubicin—hematologic cancer	7.72e-06	3.08e-05	CcSEcCtD
Fluoxetine—Urticaria—Prednisone—hematologic cancer	7.71e-06	3.08e-05	CcSEcCtD
Fluoxetine—Leukopenia—Doxorubicin—hematologic cancer	7.7e-06	3.08e-05	CcSEcCtD
Fluoxetine—Headache—Triamcinolone—hematologic cancer	7.69e-06	3.07e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Prednisone—hematologic cancer	7.67e-06	3.06e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Prednisone—hematologic cancer	7.67e-06	3.06e-05	CcSEcCtD
Fluoxetine—Confusional state—Epirubicin—hematologic cancer	7.65e-06	3.06e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Betamethasone—hematologic cancer	7.62e-06	3.04e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Dexamethasone—hematologic cancer	7.62e-06	3.04e-05	CcSEcCtD
Fluoxetine—Palpitations—Doxorubicin—hematologic cancer	7.6e-06	3.04e-05	CcSEcCtD
Fluoxetine—Anaphylactic shock—Epirubicin—hematologic cancer	7.59e-06	3.03e-05	CcSEcCtD
Fluoxetine—Hypotension—Methotrexate—hematologic cancer	7.58e-06	3.03e-05	CcSEcCtD
Fluoxetine—Loss of consciousness—Doxorubicin—hematologic cancer	7.56e-06	3.02e-05	CcSEcCtD
Fluoxetine—Infection—Epirubicin—hematologic cancer	7.54e-06	3.01e-05	CcSEcCtD
Fluoxetine—Cough—Doxorubicin—hematologic cancer	7.51e-06	3e-05	CcSEcCtD
Fluoxetine—Shock—Epirubicin—hematologic cancer	7.47e-06	2.98e-05	CcSEcCtD
Fluoxetine—Convulsion—Doxorubicin—hematologic cancer	7.45e-06	2.98e-05	CcSEcCtD
Fluoxetine—Thrombocytopenia—Epirubicin—hematologic cancer	7.43e-06	2.97e-05	CcSEcCtD
Fluoxetine—Hypertension—Doxorubicin—hematologic cancer	7.43e-06	2.97e-05	CcSEcCtD
Fluoxetine—Tachycardia—Epirubicin—hematologic cancer	7.41e-06	2.96e-05	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	7.39e-06	2.95e-05	CcSEcCtD
Fluoxetine—Skin disorder—Epirubicin—hematologic cancer	7.37e-06	2.94e-05	CcSEcCtD
Fluoxetine—Dizziness—Betamethasone—hematologic cancer	7.37e-06	2.94e-05	CcSEcCtD
Fluoxetine—Dizziness—Dexamethasone—hematologic cancer	7.37e-06	2.94e-05	CcSEcCtD
Fluoxetine—Hyperhidrosis—Epirubicin—hematologic cancer	7.34e-06	2.93e-05	CcSEcCtD
Fluoxetine—Insomnia—Methotrexate—hematologic cancer	7.33e-06	2.93e-05	CcSEcCtD
Fluoxetine—Arthralgia—Doxorubicin—hematologic cancer	7.33e-06	2.93e-05	CcSEcCtD
Fluoxetine—Chest pain—Doxorubicin—hematologic cancer	7.33e-06	2.93e-05	CcSEcCtD
Fluoxetine—Myalgia—Doxorubicin—hematologic cancer	7.33e-06	2.93e-05	CcSEcCtD
Fluoxetine—Anxiety—Doxorubicin—hematologic cancer	7.3e-06	2.92e-05	CcSEcCtD
Fluoxetine—Nausea—Triamcinolone—hematologic cancer	7.29e-06	2.91e-05	CcSEcCtD
Fluoxetine—Paraesthesia—Methotrexate—hematologic cancer	7.28e-06	2.91e-05	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	7.27e-06	2.91e-05	CcSEcCtD
Fluoxetine—Discomfort—Doxorubicin—hematologic cancer	7.24e-06	2.89e-05	CcSEcCtD
Fluoxetine—Anorexia—Epirubicin—hematologic cancer	7.23e-06	2.89e-05	CcSEcCtD
Fluoxetine—Dyspnoea—Methotrexate—hematologic cancer	7.23e-06	2.89e-05	CcSEcCtD
Fluoxetine—Somnolence—Methotrexate—hematologic cancer	7.21e-06	2.88e-05	CcSEcCtD
Fluoxetine—Dry mouth—Doxorubicin—hematologic cancer	7.16e-06	2.86e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Prednisone—hematologic cancer	7.15e-06	2.86e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Methotrexate—hematologic cancer	7.14e-06	2.85e-05	CcSEcCtD
Fluoxetine—Hypotension—Epirubicin—hematologic cancer	7.09e-06	2.83e-05	CcSEcCtD
Fluoxetine—Vomiting—Betamethasone—hematologic cancer	7.08e-06	2.83e-05	CcSEcCtD
Fluoxetine—Vomiting—Dexamethasone—hematologic cancer	7.08e-06	2.83e-05	CcSEcCtD
Fluoxetine—Confusional state—Doxorubicin—hematologic cancer	7.08e-06	2.83e-05	CcSEcCtD
Fluoxetine—Decreased appetite—Methotrexate—hematologic cancer	7.05e-06	2.82e-05	CcSEcCtD
Fluoxetine—Rash—Betamethasone—hematologic cancer	7.03e-06	2.81e-05	CcSEcCtD
Fluoxetine—Rash—Dexamethasone—hematologic cancer	7.03e-06	2.81e-05	CcSEcCtD
Fluoxetine—Anaphylactic shock—Doxorubicin—hematologic cancer	7.02e-06	2.8e-05	CcSEcCtD
Fluoxetine—Dermatitis—Betamethasone—hematologic cancer	7.02e-06	2.8e-05	CcSEcCtD
Fluoxetine—Dermatitis—Dexamethasone—hematologic cancer	7.02e-06	2.8e-05	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Methotrexate—hematologic cancer	7e-06	2.8e-05	CcSEcCtD
Fluoxetine—Fatigue—Methotrexate—hematologic cancer	6.99e-06	2.79e-05	CcSEcCtD
Fluoxetine—Headache—Betamethasone—hematologic cancer	6.98e-06	2.79e-05	CcSEcCtD
Fluoxetine—Headache—Dexamethasone—hematologic cancer	6.98e-06	2.79e-05	CcSEcCtD
Fluoxetine—Infection—Doxorubicin—hematologic cancer	6.98e-06	2.79e-05	CcSEcCtD
Fluoxetine—Asthenia—Prednisone—hematologic cancer	6.96e-06	2.78e-05	CcSEcCtD
Fluoxetine—Pain—Methotrexate—hematologic cancer	6.93e-06	2.77e-05	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	6.91e-06	2.76e-05	CcSEcCtD
Fluoxetine—Shock—Doxorubicin—hematologic cancer	6.91e-06	2.76e-05	CcSEcCtD
Fluoxetine—Thrombocytopenia—Doxorubicin—hematologic cancer	6.88e-06	2.75e-05	CcSEcCtD
Fluoxetine—Pruritus—Prednisone—hematologic cancer	6.87e-06	2.74e-05	CcSEcCtD
Fluoxetine—Insomnia—Epirubicin—hematologic cancer	6.86e-06	2.74e-05	CcSEcCtD
Fluoxetine—Tachycardia—Doxorubicin—hematologic cancer	6.85e-06	2.74e-05	CcSEcCtD
Fluoxetine—Skin disorder—Doxorubicin—hematologic cancer	6.82e-06	2.72e-05	CcSEcCtD
Fluoxetine—Paraesthesia—Epirubicin—hematologic cancer	6.81e-06	2.72e-05	CcSEcCtD
Fluoxetine—Hyperhidrosis—Doxorubicin—hematologic cancer	6.79e-06	2.71e-05	CcSEcCtD
Fluoxetine—Dyspnoea—Epirubicin—hematologic cancer	6.77e-06	2.7e-05	CcSEcCtD
Fluoxetine—Somnolence—Epirubicin—hematologic cancer	6.75e-06	2.69e-05	CcSEcCtD
Fluoxetine—Anorexia—Doxorubicin—hematologic cancer	6.69e-06	2.67e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Methotrexate—hematologic cancer	6.68e-06	2.67e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Epirubicin—hematologic cancer	6.68e-06	2.67e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Prednisone—hematologic cancer	6.64e-06	2.65e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Methotrexate—hematologic cancer	6.63e-06	2.65e-05	CcSEcCtD
Fluoxetine—Nausea—Betamethasone—hematologic cancer	6.62e-06	2.64e-05	CcSEcCtD
Fluoxetine—Nausea—Dexamethasone—hematologic cancer	6.62e-06	2.64e-05	CcSEcCtD
Fluoxetine—Decreased appetite—Epirubicin—hematologic cancer	6.6e-06	2.63e-05	CcSEcCtD
Fluoxetine—Hypotension—Doxorubicin—hematologic cancer	6.56e-06	2.62e-05	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Epirubicin—hematologic cancer	6.55e-06	2.62e-05	CcSEcCtD
Fluoxetine—Fatigue—Epirubicin—hematologic cancer	6.54e-06	2.61e-05	CcSEcCtD
Fluoxetine—Pain—Epirubicin—hematologic cancer	6.49e-06	2.59e-05	CcSEcCtD
Fluoxetine—Constipation—Epirubicin—hematologic cancer	6.49e-06	2.59e-05	CcSEcCtD
Fluoxetine—Urticaria—Methotrexate—hematologic cancer	6.44e-06	2.57e-05	CcSEcCtD
Fluoxetine—Dizziness—Prednisone—hematologic cancer	6.42e-06	2.56e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Methotrexate—hematologic cancer	6.41e-06	2.56e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Methotrexate—hematologic cancer	6.41e-06	2.56e-05	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	6.4e-06	2.56e-05	CcSEcCtD
Fluoxetine—Insomnia—Doxorubicin—hematologic cancer	6.35e-06	2.54e-05	CcSEcCtD
Fluoxetine—Paraesthesia—Doxorubicin—hematologic cancer	6.31e-06	2.52e-05	CcSEcCtD
Fluoxetine—Dyspnoea—Doxorubicin—hematologic cancer	6.26e-06	2.5e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Epirubicin—hematologic cancer	6.25e-06	2.5e-05	CcSEcCtD
Fluoxetine—Somnolence—Doxorubicin—hematologic cancer	6.24e-06	2.49e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Epirubicin—hematologic cancer	6.21e-06	2.48e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Doxorubicin—hematologic cancer	6.18e-06	2.47e-05	CcSEcCtD
Fluoxetine—Vomiting—Prednisone—hematologic cancer	6.17e-06	2.46e-05	CcSEcCtD
Fluoxetine—Rash—Prednisone—hematologic cancer	6.12e-06	2.44e-05	CcSEcCtD
Fluoxetine—Dermatitis—Prednisone—hematologic cancer	6.11e-06	2.44e-05	CcSEcCtD
Fluoxetine—Decreased appetite—Doxorubicin—hematologic cancer	6.1e-06	2.44e-05	CcSEcCtD
Fluoxetine—Headache—Prednisone—hematologic cancer	6.08e-06	2.43e-05	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.06e-06	2.42e-05	CcSEcCtD
Fluoxetine—Fatigue—Doxorubicin—hematologic cancer	6.05e-06	2.42e-05	CcSEcCtD
Fluoxetine—Urticaria—Epirubicin—hematologic cancer	6.03e-06	2.41e-05	CcSEcCtD
Fluoxetine—Pain—Doxorubicin—hematologic cancer	6e-06	2.4e-05	CcSEcCtD
Fluoxetine—Constipation—Doxorubicin—hematologic cancer	6e-06	2.4e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Epirubicin—hematologic cancer	6e-06	2.4e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Epirubicin—hematologic cancer	6e-06	2.4e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Methotrexate—hematologic cancer	5.97e-06	2.39e-05	CcSEcCtD
Fluoxetine—Asthenia—Methotrexate—hematologic cancer	5.82e-06	2.32e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Doxorubicin—hematologic cancer	5.79e-06	2.31e-05	CcSEcCtD
Fluoxetine—Nausea—Prednisone—hematologic cancer	5.76e-06	2.3e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Doxorubicin—hematologic cancer	5.74e-06	2.29e-05	CcSEcCtD
Fluoxetine—Pruritus—Methotrexate—hematologic cancer	5.74e-06	2.29e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Epirubicin—hematologic cancer	5.59e-06	2.23e-05	CcSEcCtD
Fluoxetine—Urticaria—Doxorubicin—hematologic cancer	5.58e-06	2.23e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Doxorubicin—hematologic cancer	5.55e-06	2.22e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Doxorubicin—hematologic cancer	5.55e-06	2.22e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Methotrexate—hematologic cancer	5.55e-06	2.22e-05	CcSEcCtD
Fluoxetine—Asthenia—Epirubicin—hematologic cancer	5.45e-06	2.17e-05	CcSEcCtD
Fluoxetine—Pruritus—Epirubicin—hematologic cancer	5.37e-06	2.14e-05	CcSEcCtD
Fluoxetine—Dizziness—Methotrexate—hematologic cancer	5.36e-06	2.14e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Epirubicin—hematologic cancer	5.19e-06	2.07e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Doxorubicin—hematologic cancer	5.17e-06	2.07e-05	CcSEcCtD
Fluoxetine—Vomiting—Methotrexate—hematologic cancer	5.16e-06	2.06e-05	CcSEcCtD
Fluoxetine—Rash—Methotrexate—hematologic cancer	5.11e-06	2.04e-05	CcSEcCtD
Fluoxetine—Dermatitis—Methotrexate—hematologic cancer	5.11e-06	2.04e-05	CcSEcCtD
Fluoxetine—Headache—Methotrexate—hematologic cancer	5.08e-06	2.03e-05	CcSEcCtD
Fluoxetine—Asthenia—Doxorubicin—hematologic cancer	5.04e-06	2.01e-05	CcSEcCtD
Fluoxetine—Dizziness—Epirubicin—hematologic cancer	5.02e-06	2e-05	CcSEcCtD
Fluoxetine—Pruritus—Doxorubicin—hematologic cancer	4.97e-06	1.98e-05	CcSEcCtD
Fluoxetine—Vomiting—Epirubicin—hematologic cancer	4.83e-06	1.93e-05	CcSEcCtD
Fluoxetine—Nausea—Methotrexate—hematologic cancer	4.82e-06	1.92e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Doxorubicin—hematologic cancer	4.8e-06	1.92e-05	CcSEcCtD
Fluoxetine—Rash—Epirubicin—hematologic cancer	4.79e-06	1.91e-05	CcSEcCtD
Fluoxetine—Dermatitis—Epirubicin—hematologic cancer	4.78e-06	1.91e-05	CcSEcCtD
Fluoxetine—Headache—Epirubicin—hematologic cancer	4.75e-06	1.9e-05	CcSEcCtD
Fluoxetine—Dizziness—Doxorubicin—hematologic cancer	4.64e-06	1.85e-05	CcSEcCtD
Fluoxetine—Nausea—Epirubicin—hematologic cancer	4.51e-06	1.8e-05	CcSEcCtD
Fluoxetine—Vomiting—Doxorubicin—hematologic cancer	4.46e-06	1.78e-05	CcSEcCtD
Fluoxetine—Rash—Doxorubicin—hematologic cancer	4.43e-06	1.77e-05	CcSEcCtD
Fluoxetine—Dermatitis—Doxorubicin—hematologic cancer	4.42e-06	1.77e-05	CcSEcCtD
Fluoxetine—Headache—Doxorubicin—hematologic cancer	4.4e-06	1.76e-05	CcSEcCtD
Fluoxetine—Nausea—Doxorubicin—hematologic cancer	4.17e-06	1.67e-05	CcSEcCtD
Fluoxetine—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.77e-06	5.72e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.76e-06	5.69e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK3—hematologic cancer	2.72e-06	5.6e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTP1—hematologic cancer	2.71e-06	5.6e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CREB1—hematologic cancer	2.7e-06	5.57e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.69e-06	5.55e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NUP98—hematologic cancer	2.69e-06	5.54e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FGFR3—hematologic cancer	2.68e-06	5.53e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—BRAF—hematologic cancer	2.67e-06	5.5e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK14—hematologic cancer	2.66e-06	5.48e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—KRAS—hematologic cancer	2.65e-06	5.47e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCL2—hematologic cancer	2.64e-06	5.45e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ABCB1—hematologic cancer	2.63e-06	5.43e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6R—hematologic cancer	2.63e-06	5.43e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CREBBP—hematologic cancer	2.63e-06	5.42e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.61e-06	5.38e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.61e-06	5.38e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ESR1—hematologic cancer	2.6e-06	5.37e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CD44—hematologic cancer	2.6e-06	5.36e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NQO1—hematologic cancer	2.6e-06	5.36e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NUP214—hematologic cancer	2.59e-06	5.34e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.57e-06	5.31e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FN1—hematologic cancer	2.57e-06	5.31e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.56e-06	5.28e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—NCOR1—hematologic cancer	2.56e-06	5.27e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTM1—hematologic cancer	2.56e-06	5.27e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.54e-06	5.25e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NFKBIA—hematologic cancer	2.54e-06	5.25e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BAD—hematologic cancer	2.54e-06	5.25e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—MTR—hematologic cancer	2.54e-06	5.24e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.54e-06	5.24e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.54e-06	5.23e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH1—hematologic cancer	2.52e-06	5.2e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—MTHFR—hematologic cancer	2.52e-06	5.19e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CG—hematologic cancer	2.51e-06	5.18e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAP2K1—hematologic cancer	2.51e-06	5.18e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NCOR1—hematologic cancer	2.49e-06	5.15e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTM1—hematologic cancer	2.49e-06	5.15e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CD—hematologic cancer	2.49e-06	5.14e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ENO2—hematologic cancer	2.49e-06	5.13e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—hematologic cancer	2.47e-06	5.09e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CD80—hematologic cancer	2.47e-06	5.09e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CG—hematologic cancer	2.46e-06	5.08e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KIT—hematologic cancer	2.46e-06	5.08e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—NRAS—hematologic cancer	2.46e-06	5.08e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYCS—hematologic cancer	2.46e-06	5.07e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CG—hematologic cancer	2.46e-06	5.07e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.45e-06	5.06e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	2.44e-06	5.04e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—KRAS—hematologic cancer	2.44e-06	5.04e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—hematologic cancer	2.44e-06	5.03e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.42e-06	5e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTPN11—hematologic cancer	2.42e-06	4.99e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.41e-06	4.98e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.4e-06	4.95e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—FGF2—hematologic cancer	2.39e-06	4.92e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SDC1—hematologic cancer	2.36e-06	4.87e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK3—hematologic cancer	2.36e-06	4.87e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—hematologic cancer	2.36e-06	4.86e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3R1—hematologic cancer	2.35e-06	4.86e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.35e-06	4.85e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.35e-06	4.85e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CREB1—hematologic cancer	2.34e-06	4.84e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.33e-06	4.81e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.33e-06	4.81e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CREBBP—hematologic cancer	2.33e-06	4.81e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BRAF—hematologic cancer	2.31e-06	4.78e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCL2—hematologic cancer	2.29e-06	4.73e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—JAK2—hematologic cancer	2.29e-06	4.72e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6R—hematologic cancer	2.29e-06	4.72e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CREBBP—hematologic cancer	2.28e-06	4.71e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CREBBP—hematologic cancer	2.28e-06	4.7e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—MTHFR—hematologic cancer	2.26e-06	4.66e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—HRAS—hematologic cancer	2.25e-06	4.65e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—hematologic cancer	2.24e-06	4.63e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MDM2—hematologic cancer	2.23e-06	4.61e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.22e-06	4.58e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CD—hematologic cancer	2.21e-06	4.56e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—MTHFR—hematologic cancer	2.2e-06	4.55e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.2e-06	4.54e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ALB—hematologic cancer	2.18e-06	4.5e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAP2K1—hematologic cancer	2.18e-06	4.5e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MTOR—hematologic cancer	2.17e-06	4.48e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CB—hematologic cancer	2.17e-06	4.48e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTP1—hematologic cancer	2.17e-06	4.47e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CD—hematologic cancer	2.16e-06	4.47e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CD—hematologic cancer	2.16e-06	4.45e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.14e-06	4.42e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ALB—hematologic cancer	2.13e-06	4.4e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KRAS—hematologic cancer	2.12e-06	4.37e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CG—hematologic cancer	2.11e-06	4.36e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.1e-06	4.33e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3R1—hematologic cancer	2.09e-06	4.3e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.08e-06	4.29e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HRAS—hematologic cancer	2.07e-06	4.28e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FGF2—hematologic cancer	2.07e-06	4.28e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—MTHFR—hematologic cancer	2.06e-06	4.25e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ABCB1—hematologic cancer	2.05e-06	4.23e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	2.04e-06	4.22e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1B—hematologic cancer	2.04e-06	4.21e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3R1—hematologic cancer	2.04e-06	4.21e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—AKT1—hematologic cancer	2.02e-06	4.16e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CD44—hematologic cancer	2.01e-06	4.14e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NQO1—hematologic cancer	2.01e-06	4.14e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CASP3—hematologic cancer	2e-06	4.12e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—hematologic cancer	2e-06	4.12e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.99e-06	4.11e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.99e-06	4.11e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.99e-06	4.11e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—AKT1—hematologic cancer	1.99e-06	4.11e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—JAK2—hematologic cancer	1.99e-06	4.1e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—hematologic cancer	1.99e-06	4.1e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CREBBP—hematologic cancer	1.96e-06	4.04e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.95e-06	4.02e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—hematologic cancer	1.95e-06	4.01e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—JUN—hematologic cancer	1.94e-06	4.01e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MDM2—hematologic cancer	1.94e-06	4e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CB—hematologic cancer	1.92e-06	3.97e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.9e-06	3.92e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYCS—hematologic cancer	1.9e-06	3.92e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MTOR—hematologic cancer	1.89e-06	3.89e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	1.89e-06	3.89e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.89e-06	3.89e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	1.88e-06	3.88e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.88e-06	3.88e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTEN—hematologic cancer	1.88e-06	3.87e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CD—hematologic cancer	1.86e-06	3.84e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.85e-06	3.82e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	1.84e-06	3.79e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	1.83e-06	3.78e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.82e-06	3.75e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	1.8e-06	3.72e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EP300—hematologic cancer	1.79e-06	3.69e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	1.77e-06	3.65e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.76e-06	3.63e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.76e-06	3.63e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3R1—hematologic cancer	1.76e-06	3.62e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	1.75e-06	3.61e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.75e-06	3.6e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SRC—hematologic cancer	1.74e-06	3.59e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CASP3—hematologic cancer	1.74e-06	3.58e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—hematologic cancer	1.73e-06	3.58e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.73e-06	3.57e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—hematologic cancer	1.72e-06	3.56e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CREBBP—hematologic cancer	1.72e-06	3.54e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	1.7e-06	3.5e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—hematologic cancer	1.69e-06	3.49e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—JUN—hematologic cancer	1.69e-06	3.48e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—hematologic cancer	1.68e-06	3.46e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NRAS—hematologic cancer	1.68e-06	3.46e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.67e-06	3.45e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.67e-06	3.44e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTEN—hematologic cancer	1.66e-06	3.43e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALB—hematologic cancer	1.65e-06	3.4e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	1.63e-06	3.37e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	1.63e-06	3.36e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.63e-06	3.36e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTEN—hematologic cancer	1.63e-06	3.35e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CB—hematologic cancer	1.62e-06	3.34e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.62e-06	3.34e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALB—hematologic cancer	1.61e-06	3.32e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.6e-06	3.31e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	1.6e-06	3.31e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	1.59e-06	3.29e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	1.59e-06	3.28e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—EP300—hematologic cancer	1.59e-06	3.27e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.58e-06	3.27e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.58e-06	3.25e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—hematologic cancer	1.56e-06	3.22e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	1.56e-06	3.21e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EP300—hematologic cancer	1.55e-06	3.21e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.55e-06	3.2e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—EP300—hematologic cancer	1.55e-06	3.2e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.54e-06	3.17e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.54e-06	3.17e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.54e-06	3.17e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.53e-06	3.17e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.52e-06	3.14e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALB—hematologic cancer	1.51e-06	3.13e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SRC—hematologic cancer	1.51e-06	3.12e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALB—hematologic cancer	1.5e-06	3.1e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.48e-06	3.05e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	1.47e-06	3.04e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	1.46e-06	3.01e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	1.45e-06	3e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.45e-06	3e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.45e-06	2.99e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KRAS—hematologic cancer	1.44e-06	2.97e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.44e-06	2.96e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.42e-06	2.93e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTEN—hematologic cancer	1.4e-06	2.89e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	1.39e-06	2.87e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.37e-06	2.83e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.36e-06	2.8e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—hematologic cancer	1.35e-06	2.8e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	1.35e-06	2.79e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.34e-06	2.76e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—EP300—hematologic cancer	1.34e-06	2.75e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.33e-06	2.74e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	1.32e-06	2.73e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.3e-06	2.68e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALB—hematologic cancer	1.28e-06	2.65e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—hematologic cancer	1.28e-06	2.64e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTEN—hematologic cancer	1.26e-06	2.59e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	1.25e-06	2.58e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.23e-06	2.53e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTEN—hematologic cancer	1.23e-06	2.53e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HRAS—hematologic cancer	1.23e-06	2.53e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—EP300—hematologic cancer	1.2e-06	2.47e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—hematologic cancer	1.17e-06	2.42e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—hematologic cancer	1.17e-06	2.42e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—EP300—hematologic cancer	1.17e-06	2.41e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTEN—hematologic cancer	1.16e-06	2.39e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.15e-06	2.37e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.15e-06	2.37e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTEN—hematologic cancer	1.15e-06	2.36e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.14e-06	2.36e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.13e-06	2.34e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.11e-06	2.3e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—EP300—hematologic cancer	1.1e-06	2.27e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—EP300—hematologic cancer	1.09e-06	2.25e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT1—hematologic cancer	1.08e-06	2.23e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.06e-06	2.2e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.06e-06	2.18e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.02e-06	2.1e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1e-06	2.07e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALB—hematologic cancer	9.91e-07	2.04e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—hematologic cancer	9.88e-07	2.04e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTEN—hematologic cancer	9.79e-07	2.02e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AKT1—hematologic cancer	9.58e-07	1.98e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	9.47e-07	1.96e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	9.4e-07	1.94e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AKT1—hematologic cancer	9.37e-07	1.93e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—EP300—hematologic cancer	9.34e-07	1.93e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—hematologic cancer	8.87e-07	1.83e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	8.75e-07	1.8e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—hematologic cancer	8.65e-07	1.79e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	8.15e-07	1.68e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—hematologic cancer	8.08e-07	1.67e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AKT1—hematologic cancer	8.07e-07	1.66e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTEN—hematologic cancer	7.56e-07	1.56e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AKT1—hematologic cancer	7.24e-07	1.49e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—EP300—hematologic cancer	7.21e-07	1.49e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AKT1—hematologic cancer	7.07e-07	1.46e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	6.91e-07	1.43e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKT1—hematologic cancer	6.66e-07	1.37e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKT1—hematologic cancer	6.6e-07	1.36e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKT1—hematologic cancer	5.64e-07	1.16e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	5.33e-07	1.1e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKT1—hematologic cancer	4.36e-07	8.99e-06	CbGpPWpGaD
